Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirnaomics has received NIH SBIR (Small Business Innovation Research) grant to develop its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimum scar formation.
Subscribe to our email newsletter
The fund will increase the company’s effort to perfect its nanoparticle-based siRNA delivery systems and speed up the IND enabling studies for STP705.
Sirnaomics has developed nanoparticle-based siRNA delivery systems such as the self-assembled nanoparticles,the ligand-directed nanoparticles and the infrared-activated nanoparticles used as different therapeutic applicants.
The company has developed a pipeline of siRNA therapeutic products which include STP705,STP601,STP702 and STP909.
Sirnaomics President and CEO Patrick Lu said receiving an NIH SBIR grant for development of siRNA therapeutics to improve skin scarless wound healing clearly demonstrates the scientific merits of the company.
”continuous government funding is critical for the growth of a therapeutic product company like Sirnaomics, especially in the current financial environment,” Lu added.